Capecitabine monotherapy in patients with metastatic breast cancer - Single site experience and literature review;Kapecytabina w monoterapii u chorych z uogólnionym rakiem piersi - Obserwacje własne na tle danych literaturowych

Wspolczesna Onkologia

Volumn 12, Issue 8, 2008, Pages 384-387

  Załuska, Joanna ^a   Prochowska, Ewa ^a   Karczewska Dzionk, Aldona ^a   Załuski, Jerzy ^a   Wysocki, Piotr J ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Capecitabine; Metastatic breast cancer; Monotherapy

Indexed keywords

CAPECITABINE; FLUOROURACIL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; OSTEOPENIA; OVERALL SURVIVAL; POLAND; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY;

EID: 67149097804     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Krajowy Rejestr Nowotworów; URL: http://epid.coi.waw.pl/krn.
2. American Cancer Society. Cancer Facts and Figures 2008. URL: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer, v2.2008. URL: http://www.nccn.org/professionals/ physician_gls/PDF/breast.pdf.
4. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.
5. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-54.
6. Minea L, Stanceueanu DL, Cringeanu A. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004; 22. (suppl 14): 76s.
7. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155-61.
8. Kalbakis K, Kouroussis C, Kakolyris S, et al. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes. Br J Cancer 2001; 85: 798-802.
9. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11: 325-35.
10. Pierga JY, Fumoleau P, Brewer Y, et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004; 88: 117-29.
11. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367-72.
12. Verma S, Wong NS, Trudeau M, Joy A, Mackey J, Dranitsaris G, Clemons M. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol 2007; 30: 297-302.
13. Estévez LG, Batista N, Sánchez-Rovira P, Velasco A, Provencio M, León A, Dómine M, Cruz J, Rodríguez M. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 2008; 8: 149-54.
14. Hess D, Koberle D, Thurlimann B, et al. Capecitabine and vinorelbine as first-line treatment in elderly patients (>or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73: 228-37.
15. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-51.
16. Lee KS, Ro J, Nam BH, et al. A randomized phase-III trial of docetaxel/ capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 2008; 109: 481-9.
17. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-23.
18. Silva O, Lopes G, Morgenzstern D, et al. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/ neu-negative metastatic breast cancer. Clin Breast Cancer 2008; 8: 162-7.
19. Benekli M, Yildiz R, Uner A, et al. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 2007; 72: 308-13.
20. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853-8.
21. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-9.
22. Twelves C, Trigo JM, Jones R, De Rosa F, Rakhit A, Fettner S, Wright T, Baselga J. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008; 44: 419-26.